CIBC Asset Management Inc trimmed its holdings in Teva Pharmaceutical Industries Ltd (NYSE:TEVA) by 11.8% in the fourth quarter, Holdings Channel reports. The institutional investor owned 57,954 shares of the company’s stock after selling 7,776 shares during the period. CIBC Asset Management Inc’s holdings in Teva Pharmaceutical Industries were worth $1,098,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Bank of Nova Scotia lifted its holdings in Teva Pharmaceutical Industries by 8.3% during the 2nd quarter. Bank of Nova Scotia now owns 6,903 shares of the company’s stock worth $229,000 after purchasing an additional 528 shares during the last quarter. Penserra Capital Management LLC acquired a new stake in Teva Pharmaceutical Industries during the 3rd quarter worth approximately $129,000. Fieldpoint Private Securities LLC acquired a new stake in Teva Pharmaceutical Industries during the 3rd quarter worth approximately $171,000. Cetera Investment Advisers acquired a new stake in Teva Pharmaceutical Industries during the 2nd quarter worth approximately $373,000. Finally, Comprehensive Portfolio Management LLC acquired a new stake in Teva Pharmaceutical Industries during the 4th quarter worth approximately $226,000. 51.93% of the stock is owned by institutional investors.

Teva Pharmaceutical Industries Ltd (NYSE TEVA) opened at $19.27 on Tuesday. The firm has a market capitalization of $20,020.00, a price-to-earnings ratio of -1.19, a price-to-earnings-growth ratio of 1.37 and a beta of 0.59. The company has a quick ratio of 0.66, a current ratio of 0.96 and a debt-to-equity ratio of 1.20. Teva Pharmaceutical Industries Ltd has a fifty-two week low of $10.85 and a fifty-two week high of $37.94.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its quarterly earnings results on Thursday, February 8th. The company reported $0.91 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.77 by $0.14. Teva Pharmaceutical Industries had a positive return on equity of 14.52% and a negative net margin of 72.66%. The company had revenue of $5.46 billion for the quarter, compared to analyst estimates of $5.29 billion. During the same quarter last year, the company posted $1.38 EPS. The company’s revenue for the quarter was down 15.9% compared to the same quarter last year. equities research analysts anticipate that Teva Pharmaceutical Industries Ltd will post 2.73 earnings per share for the current fiscal year.

TEVA has been the subject of several research reports. Cantor Fitzgerald set a $17.00 price target on Teva Pharmaceutical Industries and gave the stock a “hold” rating in a report on Thursday, October 19th. Barclays set a $19.00 price target on Teva Pharmaceutical Industries and gave the stock a “hold” rating in a report on Friday, October 20th. Royal Bank of Canada set a $15.00 price target on Teva Pharmaceutical Industries and gave the stock a “sell” rating in a report on Friday, October 20th. Evercore ISI set a $38.00 price target on Teva Pharmaceutical Industries and gave the stock a “buy” rating in a report on Wednesday, October 25th. Finally, Mizuho reissued a “hold” rating and set a $15.00 price target on shares of Teva Pharmaceutical Industries in a report on Monday, October 30th. Ten analysts have rated the stock with a sell rating, sixteen have assigned a hold rating and seven have given a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus price target of $21.26.

ILLEGAL ACTIVITY NOTICE: “Teva Pharmaceutical Industries Ltd (TEVA) Stake Lessened by CIBC Asset Management Inc” was originally reported by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are reading this story on another website, it was stolen and republished in violation of US and international trademark and copyright laws. The correct version of this story can be read at https://theolympiareport.com/2018/02/13/teva-pharmaceutical-industries-ltd-teva-stake-lessened-by-cibc-asset-management-inc.html.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Want to see what other hedge funds are holding TEVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teva Pharmaceutical Industries Ltd (NYSE:TEVA).

Institutional Ownership by Quarter for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.